Why aren't we treating the treatable? An audit of all HIV/HCV co-infected individuals attending an HIV Clinic by Whiteley, D. et al.
Why aren't we treating the treatable? An audit of all HIV/HCV co-infected individuals
attending an HIV Clinic




Publisher's PDF, also known as Version of record
Link to publication in ResearchOnline
Citation for published version (Harvard):
Whiteley, D, Lamond, S, Rose, F, Hildreth, L, Turner, J & Leen, C 2011, 'Why aren't we treating the treatable?
An audit of all HIV/HCV co-infected individuals attending an HIV Clinic', 17th Annual Conference of the British
HIV Association (BHIVA), Bournemouth, United Kingdom, 6/04/11 - 8/04/11.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 02. Jan. 2022
Whiteley, D., Lamond, S., Rose, F., Hildreth, L., Turner, J. & Leen C.
Regional Infectious Diseases Unit (RIDU), Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU.  Contact: david.whiteley@luht.scot.nhs.uk
Why aren’t we treating the treatable?  
An audit of all HIV/HCV co-infected individuals 
attending an HIV clinic
Background
The progression of liver disease remains a significant problem in HIV/HCV co-infected individuals, and is a leading 
cause of morbidity and mortality within this population (Smit et al, 2008).  These individuals have a more rapid 
progression of liver disease than the mono-infected cohort (e.g. Macias et al, 2010).  Despite this, the uptake of 
HCV treatment in co-infected individuals remains poor and only limited data exists as to why this population 
infrequently accepts and completes treatment (Bova et al, 2010).  The publication of the BHIVA Guidelines for the 
management of co-infection (Brook et al, 2010) prompted an audit of all HIV/HCV infected individuals attending 
the Regional Infectious Diseases Unit in Edinburgh, to assess current practice against the suggested audit standards.  
A number of factors were examined, however for the purposes of this report, the uptake of treatment and the 
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Figure 2: Percentage of patients with documented 












Figure 3: HCV RNA positive co-infected 
individuals by genotype (n=113)
Figure 4: Percentage uptake for those HIV/HCV patients offered a 















Figure 4: Percentage uptake for those HIV/HCV 
patients offered a liver biopsy by HCV genotype
Experience of HCV treatment Number of Individuals 




On waiting list actively being considered/working 
up to treatment 
12 










Reason Documented Number of References 
Unknown/nothing documented 24 
Worries regarding side effects and affect 
on quality of life 
23   
Wishes to postpone at present 12 
Ambivalent/uninterested in treatment 10 
Poor success rates with current 
treatment 
9 
Currently undergoing treatment for other 
condition 
3 
Reluctant to switch HAART 1 
Awaiting CD4 count to rise 1 
Table 1: The experience of HCV RNA-positive 
co-infected individuals of HCV treatment.
Table 2: Patient reasons for not wishing to pursue 
HCV treatment as recorded in clinical notes.  Multiple 
reasons cited in some sets of case-notes.
Relative Contraindications to HCV 
treatment as per RIDU treatment 
protocol
CD4<200
Chaotic drug use/ongoing unsafe IVDU
Uncontrolled psychiatric/psychological symptoms
Pregnant or planning a pregnancy
Excessive alcohol intake
Poor attendance record
Lack of practical or emotional support
Severe thrombocytopenia
Advanced or decompensated cirrhosis
Malignancy
Autoimmune disease
Uncontrolled hypertensive or diabetic retinopathy
Methods
A total of 219 individuals who are both HIV positive and anti-HCV positive were identified from the unit database.  
A retrospective audit of these individuals’ case notes was then conducted.  Only written entries made in the last 
three years were reviewed.  Written entries included both clinical letters and also hand written entries in the 
outpatient clinical notes.  Serology was audited using the laboratory computer system APEX which allowed access 
to results back to 1999.  The design for the audit tool was based on the BHIVA audit standards for the management 
of co-infection (Brook et al, 2010).  The first sets of case-notes were audited on the 15.02.2010 and the last set on 
the 31.12.2010.  The average time between case notes being audited and the individual’s last attendance in clinic 
was 49.1 days.
Of the 219 individuals identified, 46 were excluded from the study for reasons shown in figure 1.  3 patients died 
during the course of the audit.  The remaining 173 sets of notes were audited and those individuals who were HCV 
RNA viraemic were identified.  The following results pertain only to those 113 individuals who were anti-HCV and 
HCV RNA positive.
Audit Standard 5: All HCV-infected patients should have documented evidence in their case notes of a discussion on 
alcohol avoidance and how to reduce the risks of transmission.
Figure 2 demonstrates those individuals who had documented evidence of these discussions within the last three 
years.
Audit Standard 9: All HCV RNA-positive patients should have an HCV viral load and genotype determination 
performed.
Figure 3 demonstrates the genotypes of those individuals identified as HIV/HCV RNA positive.
Audit Standard 11: All patients with chronic HCV should be offered an assessment of liver fibrosis by liver biopsy, 
hepatic elastography or other validated noninvasive fibrosis test.
For the assessment of fibrosis and the staging of liver disease, hepatic elastography has only been available on a 
limited basis locally since June 2010, therefore liver biopsy has been the standard assessment tool used during the 
audit period.  Overall, 39% of individuals had either evidence of being offered a biopsy within the last three years in 
the case-notes or had a biopsy result documented on the laboratory results system since 1999 (45% for genotypes 1 
and 4, 33% for genotypes 2 and 3).  Of those offered a biopsy, figure 4 shows the relevant uptake rates.  29% (n=33) 
of the total cohort had documentation in the medical notes indicating they appear clinically cirrhotic.  Of those, only 
21% (n=7) had been confirmed by biopsy.
Audit Standard 13:  All HCV RNA-positive patients should be considered for treatment unless there is a specific 
contraindication.
Of the 113 RNA-positive individuals, table 1 illustrates 
the breakdown of their combined experience of HCV 
treatment.  For the 72 individuals who had no experience 
of HCV treatment, table 2 details the documented 
reasons as to why it had not yet been attempted. 
Multiple reasons were cited in some sets of notes.
48 out of 72 individuals had discussion of HCV treatment 
in the notes with documented reasons as to why they 
had declined therapy to date.  A number of relative 
contraindications were also examined (see text box). 
Of the whole cohort of 72 patients with no experience 
of treatment, 23 had no relative contraindication 
to treatment documented in the notes.  Of the 48 
individuals who had declined treatment, 19 did not 
have any relative contraindications noted.  Therefore, 
4 individuals had neither discussion regarding HCV 




The side effects associated with the current HCV treatment regime of pegylated interferon and ribavirin were the 
main reasons cited by patients for declining therapy.  This is consistent with other studies which have looked at the 
factors influencing a decision to start HCV treatment (Osilla et al, 2009).  There needs to be an awareness however, 
that individuals’ attitudes, opinions and circumstances change.  As the new drugs currently in development start to 
filter through to clinical practice, with the promise of increased SVR rates and shortened treatment times, these 
favourable factors may outweigh the significant side effect profile for a number of individuals.  The topic of HCV 
treatment should therefore be revisited annually in clinic, and plans formulated to address obstacles to treatment, 
whether the individual is actively considering a course of therapy at that stage or not.  Proactive management of other 
biopsychosocial issues which could hinder HCV treatment should be encouraged amongst clinicians in readiness for 
a period of therapy, so that when an individual does consent to treatment, any relative contraindications are already 
being addressed. The documentation of these discussions and subsequent plans of care are vital.
The confirmation of cirrhosis and staging of liver fibrosis have historically been poorly conducted within the unit.  
Approximately two thirds of those offered staging by biopsy in the past accepted however; therefore as hepatic 
elastography becomes more readily available locally the uptake of this non-invasive scan will hopefully improve these 
results.  As more rapid progression of liver disease is frequently reported in this cohort (e.g. Macias et al, 2010), 
the repeated and regular use of staging tools should be a priority within this population to monitor progression of 
liver disease.
Conclusions
♦ The staging of liver disease has historically been poorly conducted within the unit.  The arrival of hepatic  
 elastography however should help to improve this.  Clinicians have been made aware of the audit results to  
 improve practice.
♦ 72 out of 113 HCV RNA positive co-infected individuals have no experience of treatment to date.  Of these  
 72 individuals however, only 5.6% (n=4) have neither a discussion regarding HCV treatment and a reason for  
 declining, or a relative contraindication documented in their notes.
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